Vestmark Advisory Solutions
TELO icon

Vestmark Advisory Solutions’s Telomir Pharmaceuticals TELO Stock Holding History

Vestmark Advisory Solutions’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.4K Buy
13,600
+500
+4% +$651 ﹤0.01% 1461
2026
Q1 		$17K Hold
13,100
– – ﹤0.01% 1324
2025
Q4 		$17.4K Buy
+13,100
New +$18.9K ﹤0.01% 1239

Other funds holding TELO

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
World Investment Advisors
World Investment Advisors Santa Barbara, California $6.04B AUM 22.7% 1-Year Est. Return

Vestmark Advisory Solutions's TELO Position: Q2 2026 in Review

Vestmark Advisory Solutions increased its Telomir Pharmaceuticals (TELO) stake by 3.8% in Q2 2026, buying an estimated $651 and bringing the position to 13,600 shares worth $17.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1461.

Vestmark Advisory Solutions first reported a position in TELO in Q4 2025 and has held it in 3 quarters since. The position peaked at $17.4K in Q4 2025. 33 funds tracked by Wall St. Rank hold TELO as of Q2 2026.

  • Vestmark Advisory Solutions held 13,600 shares of Telomir Pharmaceuticals worth $17.4K as of Q2 2026.
  • Vestmark Advisory Solutions bought 500 Telomir Pharmaceuticals shares in Q2 2026, an estimated $651.
  • Telomir Pharmaceuticals made up ﹤0.01% of Vestmark Advisory Solutions's portfolio in Q2 2026, its #1461 holding.
  • Vestmark Advisory Solutions first reported a position in Telomir Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Vestmark Advisory Solutions's Telomir Pharmaceuticals position peaked at $17.4K in Q4 2025.
  • 33 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q2 2026.

Based on Vestmark Advisory Solutions's 13F filing for Q2 2026, filed 14 Aug 2026.